THERACLION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.522 EUR | +0.77% |
|
+41.08% | +34.54% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.48M 1.59M | Sales 2022 | 1.24M 1.33M | Capitalization | 26.15M 28.16M |
|---|---|---|---|---|---|
| Net income 2021 | -3M -3.23M | Net income 2022 | -4M -4.31M | EV / Sales 2021 | 24.8 x |
| Net Debt 2021 | 6.99M 7.53M | Net Debt 2022 | 6.52M 7.03M | EV / Sales 2022 | 26.4 x |
| P/E ratio 2021 |
-7.93
x | P/E ratio 2022 |
-5.35
x | Employees | 30 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 71.21% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.77% | ||
| 1 week | +41.08% | ||
| Current month | +42.23% | ||
| 1 month | +42.62% | ||
| 3 months | +2.35% | ||
| 6 months | +6.53% | ||
| Current year | +34.54% |
1 week
0.37
0.57
1 month
0.340.57
Current year
0.310.68
1 year
0.300.85
3 years
0.302.28
5 years
0.302.76
10 years
0.3014.00
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Deterre
CEO | Chief Executive Officer | - | 19-12-31 |
Laurence Géricot
DFI | Director of Finance/CFO | - | - |
Gaylord Tallec
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ari Kellen
BRD | Director/Board Member | - | 19-02-12 |
Renaud Saleur
BRD | Director/Board Member | - | 18-01-31 |
Yann Duchesne
CHM | Chairman | 67 | 22-01-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.522 | +0.77% | 59,204 |
| 24-05-09 | 0.518 | +17.73% | 104,932 |
| 24-05-08 | 0.44 | +7.32% | 19,627 |
| 24-05-07 | 0.41 | +2.76% | 60,877 |
| 24-05-06 | 0.399 | +7.84% | 47,252 |
Real-time Euronext Paris, May 10, 2024 at 11:28 am EDT
More quotes
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows:
- sale of equipment (61.8%);
- sale of consumables (29%);
- provision of after-sales services (9.2%).
Export accounts for 99.7% of net sales.
Calendar
2024-09-18
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.54% | 25.49M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- ALTHE Stock